Tag: Big Pharma

Pharmaceutical companies are radically redesigning portfolio strategies to survive a "triple threat" environment of scientific complexity, regulatory upheaval like the IRA, and capital scarcity. This analysis explores the shift from efficiency-driven models to resilience-first frameworks, detailing how leaders are embedding optionality into pipelines, embracing modality agnosticism, and using dynamic resource allocation to thrive amidst volatility.

A new agreement as per which Eli Lilly and Company is going to offer almost $40 million to Indiana University - IU has come...

Regeneron Pharmaceuticals is going ahead and investing more funds into gene editing, as it has announced a collaboration with Tessera Therapeutics in December 2025,...

The Trump administration has lined up yet another country-specific trade agreement, and this time it is going to be with the U.K., which confers...

Eli Lilly, the US pharma giant, has become the first drugmaker to hit $1tn valuation on November 22, 2025, hence entering the exclusive club,...

Samsung Biologics announced on November 26, 2025, that it has gone on to achieve a whopping 400 regulatory manufacturing approvals all over the world due to...

Datroway, a cancer drug developed by AstraZeneca and Daiichi Sankyo, has demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints...